Immunoglobulin E specific for grass pollen allergens (IgE)

Human IgE antibodies specific for grass pollen allergens are the primary mediators of seasonal allergic rhinitis and allergic asthma in sensitized individuals. These antibodies are produced by B cells in response to proteins from the Poaceae family, such as Timothy grass (Phleum pratense) allergens Phl p 1 and Phl p 5 (Crameri et al., 2014). Once produced, these IgE molecules bind to the high-affinity FcεRI receptors on mast cells and basophils. Upon re-exposure to grass pollen, the allergens cross-link the receptor-bound IgE, triggering the immediate release of inflammatory mediators like histamine and leukotrienes (Galli & Tsai, 2012). This cascade results in the classic symptoms of hay fever, including sneezing, rhinorrhea, and bronchial constriction. Therapeutic interventions like Omalizumab target the Fc region of circulating IgE, preventing it from binding to its receptors and effectively dampening the allergic response (Bousquet et al., 2011). Allergen-specific immunotherapy (AIT) also targets this pathway by inducing blocking IgG4 antibodies that compete with IgE for allergen binding (Shamji & Durham, 2017).

Other names

Grass pollen-specific IgEsIgE to grass pollenAnti-grass pollen IgEAllergen-specific IgE

Monoclonal antibodies like Omalizumab bind to the Cε3 domain of circulating IgE, preventing its interaction with the high-affinity FcεRI receptor on mast cells and basophils (Bousquet et al., 2011). This sequestration reduces the density of FcεRI receptors on effector cells and inhibits the release of inflammatory mediators upon allergen exposure (Galli & Tsai, 2012). Additionally, some therapies target the M1-prime segment of membrane-bound IgE to deplete IgE-producing B cells (Gauvreau et al., 2014).